A PHP Error was encountered

Severity: Warning

Message: fopen(/var/lib/php/sessions/ci_sessionp9d9akl0inbqaj9l7015tri2evfk6rp8): Failed to open stream: No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 177

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)

Filename: Session/Session.php

Line Number: 137

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once

Safety and efficacy of pegcetacoplan treatment for cold agglutinin disease and warm antibody autoimmune hemolytic anemia. | LitMetric

AI Article Synopsis

  • This study tested pegcetacoplan, a targeted therapy aimed at treating these conditions, over 48 weeks in two patient groups with CAD and wAIHA who received either 270 or 360 mg/day.
  • Results showed that pegcetacoplan was generally well tolerated with minimal serious side effects, and it effectively increased hemoglobin levels and reduced hemolysis in both groups.

Article Abstract

Cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA) are rare autoimmune hemolytic anemias characterized by red blood cell destruction, largely attributable to complement activation resulting in intravascular and extravascular hemolysis. Pegcetacoplan is a subcutaneously administered C3-targeted therapy, which may be suitable for treating CAD and wAIHA. In this open-label phase 2 study, analyses were conducted in two cohorts, one for patients with CAD and the other wAIHA. In each cohort, patients were randomly assigned to receive 270 or 360 mg/day pegcetacoplan for up to 48 weeks. Safety endpoints included the incidence and severity of treatment-emergent adverse events (TEAEs) and adverse events of special interest (AESI). Efficacy endpoints included change from baseline in hemoglobin (Hb), lactate dehydrogenase, absolute reticulocyte count, haptoglobin, indirect bilirubin, and Functional Assessment of Chronic Illness Therapy (FACIT)-fatigue scale. Thirteen (100%) and 10 out of 11 (91%) patients with CAD and wAIHA respectively experienced at least 1 TEAE. Ten patients had at least 1 serious adverse event; none were considered related to pegcetacoplan. The only treatment-related AESIs were injection site reactions. Pegcetacoplan increased Hb levels, reduced hemolysis, and increased FACIT-fatigue scale scores in the first weeks; at week 48 the median (interquartile range) change from baseline Hb for the CAD and wAIHA total groups was 2.4 (0.90 to 3.00) and 1.7 g/dL (‑1.40 to 2.90), respectively, and improvements in hemolysis and FACIT-fatigue scale scores were maintained. This study demonstrated that pegcetacoplan is generally well tolerated and suggests it can be effective in patients with CAD and wAIHA. Registered at www.clinicaltrials.gov (NCT03226678).

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2023022549DOI Listing

Publication Analysis

Top Keywords

cad waiha
20
autoimmune hemolytic
12
patients cad
12
facit-fatigue scale
12
cold agglutinin
8
agglutinin disease
8
warm antibody
8
antibody autoimmune
8
hemolytic anemia
8
endpoints included
8

Similar Publications

Autoimmune haemolytic anaemias.

Nat Rev Dis Primers

November 2024

Hematology Unit, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

Adult autoimmune haemolytic anaemias (AIHAs) include different subtypes of a rare autoimmune disease in which autoantibodies targeting autoantigens expressed on the membrane of autologous red blood cells (RBCs) are produced, leading to their accelerated destruction. In the presence of haemolytic anaemia, the direct antiglobulin test is the cornerstone of AIHA diagnosis. AIHAs are classified according to the isotype and the thermal optimum of the autoantibody into warm (wAIHAs), cold and mixed AIHAs.

View Article and Find Full Text PDF
Article Synopsis
  • This study tested pegcetacoplan, a targeted therapy aimed at treating these conditions, over 48 weeks in two patient groups with CAD and wAIHA who received either 270 or 360 mg/day.
  • Results showed that pegcetacoplan was generally well tolerated with minimal serious side effects, and it effectively increased hemoglobin levels and reduced hemolysis in both groups.
View Article and Find Full Text PDF

Autoimmune Hemolytic Anemias: Challenges in Diagnosis and Therapy.

Transfus Med Hemother

October 2024

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Article Synopsis
  • Autoimmune hemolytic anemia (AIHA) is a rare condition characterized by the destruction of red blood cells due to autoantibodies, with two main types: warm AIHA (wAIHA) and cold agglutinin disease (CAD).
  • Diagnosis relies on the direct antiglobulin test (DAT), which shows different results depending on the type of AIHA, affecting treatment options, as steroids work for wAIHA, but less so for CAD.
  • The article discusses the varying clinical presentations and treatment challenges for AIHA, highlighting new therapies currently in trials for those who do not respond to standard treatments.
View Article and Find Full Text PDF

Autoimmune hemolytic anemia (AIHA) is characterized by the accelerated destruction of erythrocytes due to the presence of antibodies and/or complement that bind to antigens on erythrocytes. It can be subdivided into warm, cold or mixed AIHA based on the type of autoantibody and the optimal temperature of antigen-antibody reaction. Glucocorticoid with or without rituximab is the first-line treatment of warm AIHA (wAIHA), and splenectomy was once the preferred second-line treatment for relapsed or refractory wAIHA.

View Article and Find Full Text PDF
Article Synopsis
  • Autoimmune hemolytic anemias (AIHAs) involve the immune system producing antibodies that attack the body's own red blood cells, categorized mainly into warm and cold antibody types, as well as mixed forms.
  • Treatment varies depending on the type, often including glucocorticoids and monoclonal antibodies, with the direct antiglobulin test (DAT) playing a key role in diagnosis.
  • Additional complexities include drug-induced AIHA and conditions like passenger lymphocyte syndrome, highlighting the need for tailored management strategies based on the specific AIHA category.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!